SCHEMBL2214754

SCHEMBL2214754

CC(=O)N(Sc1nc(-c2cccc(-c3csc(N)n3)c2)c(Br)s1)C1CCN(Cc2ccc(Cl)c(Cl)c2)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR3 P51677 4/20 0.39
CCR1 P32246 3/20 0.39
SMN1; SMN2 Q16637 2/20 0.35
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.34
BCHE P06276 1/20 0.34
ACHE P22303 1/20 0.34
GSK3B P49841 1/20 0.34
SIGMAR1 Q99720 2/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
DRD2 P14416 1/20 0.34
DRD4 P21917 1/20 0.34
HTR2A P28223 1/20 0.34
PARP1 P09874 1/20 0.34
PARP2 Q9UGN5 1/20 0.34
LCK P06239 1/20 0.34
CSF1R P07333 1/20 0.34
CHRM2 P08172 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2213659 0.90 CCR1 (0.41) CCR3CCR1SMN1; SMN2KDM4EALDH1A1
SCHEMBL2210860 0.84 PARP1 (0.42) CCR3CCR1SMN1; SMN2KDM4EALDH1A1
SCHEMBL2207876 0.84 CCR1 (0.43) CCR3CCR1SMN1; SMN2KDM4EALDH1A1
SCHEMBL2213567 0.84 CCR3 (0.43) CCR3CCR1SMN1; SMN2KDM4EALDH1A1
SCHEMBL2214230 0.82 CCR3 (0.43) CCR3CCR1SMN1; SMN2KDM4EALDH1A1
SCHEMBL2214752 0.82 CCR3 (0.61) CCR3CCR1SIGMAR1MEN1KMT2A
SCHEMBL2212825 0.82 KMT2A (0.42) CCR3CCR1SMN1; SMN2KDM4EALDH1A1
SCHEMBL2214004 0.81 CCR3 (0.41) CCR3CCR1SMN1; SMN2KDM4EALDH1A1
SCHEMBL2214181 0.81 CCR3 (0.41) CCR3CCR1SMN1; SMN2KDM4EALDH1A1
SCHEMBL2210711 0.80 CCR3 (0.45) CCR3CCR1SMN1; SMN2KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1389616-B1 3,4-Dihalobenzylpiperidine derivatives and their medical use MITSUBISHI TANABE PHARMA CORP (JP) 2011-07-27 EP disclosed
US-7115635-B2 Benzylpiperidine compound MITSUBISHI PHARMA CORPORATION (JP) 2006-10-03 US disclosed
US-20040158071-A1 Chemokine inhibitors and stability in blood MITSUBISHI PHARMA CORPORATION (JP) 2004-08-12 US disclosed
EP-1389616-A1 NOVEL BENZYLPIPERIDINE COMPOUND Mitsubishi Pharma Corporation (JP) 2004-02-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040158071-A1 Chemokine inhibitors and stability in blood CCL2, CXCR1, CCR5 CCR3 21/4885CCR1 11/4885SMN1; SMN2 3712/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.